Thank you very much sir .
You could upload the media on a drop box and share the details hereconcall available on research byte
dear mr. sumit
could you please forward the same to email address vineeethgn@gmail.com
thanks and regards
Please try this link and let me know if you can access the fild
“https://www.dropbox.com/l/scl/AABkk3etAXnMuS6gCTeFwC6QV0Rw2xkBMqA”
1 Like
Hi,
As per what I can recall -
- Total 11 patents are with Omkar Speciality and 4 have been granted.
To add - 25% revenues are coming already coming from patented products and we can see 30% revenues coming from patented products.
- Inter-se transfer of 10% stake to happen after some time
- Newly launched products to have gross margin of 30%-35%.
- Capacities are fungible.
- No capex planned. Only maintenance capex of 4-5 crs per year.
- Promoter stake currently at 38%
- Would be ingredients provider in flavour and fragrance and would be used in formulations. Flavours would be for food, confectionery, soft drinks, biscuits.
- Current commitments more on exports front
- Scale up of nutraceuticals products is what they are looking for
- Tax rate is 30%
- Un-utilized MAT credit is 6 Crores
- GST is going to beneficial. earlier excise and VAT of 12.5% & 6%.Couldn’t understand it clearly due to voice issue.
- Due to repayment of long term loans finance cost has come down.
- Inter-se transfer in blood-relation so transfer would be as a gift and no monetary consideration.
- Selling the new products directly, selling through distributors only if payment cycle is a problem.
- 15% revenue growth Y-o-Y. EBITDA to be maintained.
- Currently payable days is 91 days have come down from 94 days.
- Cash is 10 crores
- Other expenses - Excise duty has reduced as a result of selling of non-excise duty good to pharmaceutical companies. Other expenses include excise duty.
Disclosure - Invested
Regards
Krishna
12 Likes
Lasa Listing update
In-Principle approval for listing of 22,864,449 Equity Shares of Rs.10/- each of Lasa Supergenerics Ltd. pursuant to Composite Scheme of Arrangement.
http://www.bseindia.com/xml-data/corpfiling/AttachLive/b36c0eeb-6d57-43c1-839f-7bc348e92ef7.pdf
3 Likes
Omkar Speciality Chemicals announced that the Department of Scientific and Industrial Research has accepted the application of the Company for renewal of recognition to the in-house R&D unit of the Company located at Badlapur, Thane. The recognition and registration of the in-house R&D unit is renewed up to 31 March 2020.
Great improvement in margin.
If not for deferred tax, PAT would had been excellent. Still it would help later.
The deferred tax is nearly 4 crores. If we add this back to the profits , then the PAT increases to 9 crores copared to 5.38 crores of last year. If it continues on its high growth path, then we might hve fy18 sales of 300 crores and Net profit of around 25 crores.
2 Likes
In q1 , Sequent scientific has made a profit of 5.53 crores on sales of 111 crores. The equity capital is 48.75 crores and the fv is 2. So the eps works out to be 20 paise per share. The scrip quotes at 116 or a pe ratio of 580 times. When compared to LASA , Sequent has a profile that matches LASA very closely.As compared to Sequent LASA has made a profit of 5 crores on a sales of 60 crores and is growng at a scorching pace. If we add the deferred tax back to profits then the profits increase to 9 crores. A NPM of 15 % compared to 4.5 % of Sequent.
3 Likes
Small correction. At 15% NPM, NP is 45 Cr for top line of 300 Cr. Impressive performance of company. Bothered about procedural delay in listing (when compared to timelines of Sintex)
2 Likes
The opm is 15 %, if we add the deferred tax to profits. However assuming that taxes will eat some of the profits, it is safer to take a NPM of 8 to 10 %, hence a NP of 25 crores. Any upside from 25 crores will be a pleasant surprise.
2 Likes
Hi Krishna, Thanks for the update. Any update provided by the management on commencement of production in Unit V at concall.
Hi,
They had mentioned something about plant V but I dont remember exactly. Plant V is for Lasa.
Unit V of LASA will probably start immediately after LASA is listed and the capacity of LASA might become almost double of the current production capacity , as a result.
How is lasa able to post such good numbers if unit 5 is not working.?
Lasa posted good number on annual ( YOY) basis and not Quarterly ( QOQ) basis. It is almost same QOQ basis.
Unit V will be an addition. Already LASA has units producing veterinary API. Till it achieves 100% capacity utilization, growth will be there. Moreover it is also shifting to higher end products with greater value addition, leading to better margins.Unit V, which will probably start sometime in q3, will lead to a big jump in production capacity